|
Long Term Customers Continue to Propel OmniComm’s Fast-Paced Growth
- TrialMaster EDC Solution Selected for Enterprise-Wide Phase I Trials -
Fort Lauderdale, FL, February 23, 2010 - OmniComm Systems, Inc.
(OTC: OMCM.OB), a global provider of eClinical solutions,
announced today that a top five U.S. based Biotech Company has expanded its relationship
by signing an enterprise-wide agreement to deploy OmniComm’s TrialMaster EDC solution
for its early phase studies. The total revenue from this agreement is expected to
surpass $750,000 during its first year.
"We look forward to continuing our successful collaboration with this customer,"
remarked Stephen Johnson, COO of OmniComm Systems. "Our flagship EDC solution, TrialMaster,
has already proven to be an efficient and reliable data capture system for nearly
50 of this customer’s studies during the past 2 years." Johnson added, "This is
proof positive that the high quality of our EDC solutions and our outstanding customer
service, continue to generate the high percentage of return business needed to sustain
our current rate of growth."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm's client intuitive pricing
model allows companies that range from small, to mid-size to large-scale institutions
to efficiently capitalize on their clinical research investments. OmniComm Systems,
Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn,
Germany, with satellite offices in New Jersey and the United Kingdom, as well as
sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may
constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties
such as the Company's ability to obtain new contracts and accurately estimate net
revenues due to uncertain regulatory guidance, variability in size, scope and duration
of projects, and internal issues at the sponsoring client, integration of acquisitions,
competitive factors, technological development, and market demand. As a result,
actual results may differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the Company's financial
results can be found in the Company's Reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future
events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
